Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 287 entries
Sorted by: Best Match Show Resources per page
Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.

Breast cancer research and treatment

van Ramshorst MS, van der Heiden-van der Loo M, Dackus GM, Linn SC, Sonke GS.
PMID: 27534944
Breast Cancer Res Treat. 2016 Sep;159(2):393. doi: 10.1007/s10549-016-3941-6.

No abstract available.

Cite
van Ramshorst MS, van der Heiden-van der Loo M, Dackus GM, et al. Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. Breast Cancer Res Treat. 2016;159(2):393doi: 10.1007/s10549-016-3941-6.
van Ramshorst, M. S., van der Heiden-van der Loo, M., Dackus, G. M., Linn, S. C., & Sonke, G. S. (2016). Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. Breast cancer research and treatment, 159(2), 393. https://doi.org/10.1007/s10549-016-3941-6
van Ramshorst, Mette S, et al. "Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer." Breast cancer research and treatment vol. 159,2 (2016): 393. doi: https://doi.org/10.1007/s10549-016-3941-6
van Ramshorst MS, van der Heiden-van der Loo M, Dackus GM, Linn SC, Sonke GS. Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. Breast Cancer Res Treat. 2016 Sep;159(2):393. doi: 10.1007/s10549-016-3941-6. PMID: 27534944.
Copy Download .nbib Format: NLM
Erratum to: Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient.

Breast cancer research and treatment

Churilla TM, Egleston BL, Murphy CT, Sigurdson ER, Hayes SB, Goldstein LJ, Bleicher RJ.
PMID: 27766452
Breast Cancer Res Treat. 2016 Dec;160(3):573. doi: 10.1007/s10549-016-4023-5.

No abstract available.

Cite
Churilla TM, Egleston BL, Murphy CT, et al. Erratum to: Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient. Breast Cancer Res Treat. 2016;160(3):573doi: 10.1007/s10549-016-4023-5.
Churilla, T. M., Egleston, B. L., Murphy, C. T., Sigurdson, E. R., Hayes, S. B., Goldstein, L. J., & Bleicher, R. J. (2016). Erratum to: Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient. Breast cancer research and treatment, 160(3), 573. https://doi.org/10.1007/s10549-016-4023-5
Churilla, Thomas M, et al. "Erratum to: Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient." Breast cancer research and treatment vol. 160,3 (2016): 573. doi: https://doi.org/10.1007/s10549-016-4023-5
Churilla TM, Egleston BL, Murphy CT, Sigurdson ER, Hayes SB, Goldstein LJ, Bleicher RJ. Erratum to: Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient. Breast Cancer Res Treat. 2016 Dec;160(3):573. doi: 10.1007/s10549-016-4023-5. PMID: 27766452.
Copy Download .nbib Format: NLM
Retraction Note to: Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin. Breast Cancer Res Treat (2014) 147:203-10.

Breast cancer research and treatment

[No authors listed]
PMID: 25929763
Breast Cancer Res Treat. 2015 Jun;151(2):479. doi: 10.1007/s10549-015-3399-y.

No abstract available.

Cite
Retraction Note to: Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin. Breast Cancer Res Treat (2014) 147:203-10. Breast Cancer Res Treat. 2015;151(2):479doi: 10.1007/s10549-015-3399-y.
(2015). Retraction Note to: Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin. Breast Cancer Res Treat (2014) 147:203-10. Breast cancer research and treatment, 151(2), 479. https://doi.org/10.1007/s10549-015-3399-y
"Retraction Note to: Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin. Breast Cancer Res Treat (2014) 147:203-10." Breast cancer research and treatment vol. 151,2 (2015): 479. doi: https://doi.org/10.1007/s10549-015-3399-y
Retraction Note to: Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin. Breast Cancer Res Treat (2014) 147:203-10. Breast Cancer Res Treat. 2015 Jun;151(2):479. doi: 10.1007/s10549-015-3399-y. PMID: 25929763.
Copy Download .nbib Format: NLM
Erratum to: Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients.

Breast cancer research and treatment

Tang J, Deng R, Luo RZ, Shen GP, Cai MY, Du ZM, Jiang S, Yang MT, Fu JH, Zhu XF.
PMID: 26960710
Breast Cancer Res Treat. 2016 Apr;156(2):403-4. doi: 10.1007/s10549-016-3703-5.

Erratum to: Breast Cancer Res Treat (2012),134:549–560,DOI 10.1007/s10549-012-2080-y. In the original publication of the article, Fig. 5c was published incorrectly. The authors apologize for this error and the correct Fig. 5c is given below.

Cite
Tang J, Deng R, Luo RZ, et al. Erratum to: Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients. Breast Cancer Res Treat. 2016;156(2):403-4doi: 10.1007/s10549-016-3703-5.
Tang, J., Deng, R., Luo, R. Z., Shen, G. P., Cai, M. Y., Du, Z. M., Jiang, S., Yang, M. T., Fu, J. H., & Zhu, X. F. (2016). Erratum to: Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients. Breast cancer research and treatment, 156(2), 403-4. https://doi.org/10.1007/s10549-016-3703-5
Tang, Jun, et al. "Erratum to: Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients." Breast cancer research and treatment vol. 156,2 (2016): 403-4. doi: https://doi.org/10.1007/s10549-016-3703-5
Tang J, Deng R, Luo RZ, Shen GP, Cai MY, Du ZM, Jiang S, Yang MT, Fu JH, Zhu XF. Erratum to: Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients. Breast Cancer Res Treat. 2016 Apr;156(2):403-4. doi: 10.1007/s10549-016-3703-5. PMID: 26960710.
Copy Download .nbib Format: NLM
Retraction Note to: Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-κB signaling pathways.

Breast cancer research and treatment

Ahmad A, Wang Z, Kong D, Ali R, Ali S, Banerjee S, Sarkar FH.
PMID: 27412557
Breast Cancer Res Treat. 2016 Aug;158(3):605. doi: 10.1007/s10549-016-3905-x.

No abstract available.

Cite
Ahmad A, Wang Z, Kong D, et al. Retraction Note to: Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-κB signaling pathways. Breast Cancer Res Treat. 2016;158(3):605doi: 10.1007/s10549-016-3905-x.
Ahmad, A., Wang, Z., Kong, D., Ali, R., Ali, S., Banerjee, S., & Sarkar, F. H. (2016). Retraction Note to: Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-κB signaling pathways. Breast cancer research and treatment, 158(3), 605. https://doi.org/10.1007/s10549-016-3905-x
Ahmad, Aamir, et al. "Retraction Note to: Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-κB signaling pathways." Breast cancer research and treatment vol. 158,3 (2016): 605. doi: https://doi.org/10.1007/s10549-016-3905-x
Ahmad A, Wang Z, Kong D, Ali R, Ali S, Banerjee S, Sarkar FH. Retraction Note to: Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-κB signaling pathways. Breast Cancer Res Treat. 2016 Aug;158(3):605. doi: 10.1007/s10549-016-3905-x. PMID: 27412557.
Copy Download .nbib Format: NLM
Erratum to: The latest is the greatest? Results of a structured lecture about aromatase inhibitor use for breast cancer.

Breast cancer research and treatment

Gainford MC, McCready D, Clemons M.
PMID: 28303486
Breast Cancer Res Treat. 2006 Apr;96(3):207. doi: 10.1007/s10549-006-9165-4. Epub 2006 Mar 16.

No abstract available.

Cite
Gainford MC, McCready D, Clemons M. Erratum to: The latest is the greatest? Results of a structured lecture about aromatase inhibitor use for breast cancer. Breast Cancer Res Treat. 2006;96(3):207doi: 10.1007/s10549-006-9165-4.
Gainford, M. C., McCready, D., & Clemons, M. (2006). Erratum to: The latest is the greatest? Results of a structured lecture about aromatase inhibitor use for breast cancer. Breast cancer research and treatment, 96(3), 207. https://doi.org/10.1007/s10549-006-9165-4
Gainford, M C, et al. "Erratum to: The latest is the greatest? Results of a structured lecture about aromatase inhibitor use for breast cancer." Breast cancer research and treatment vol. 96,3 (2006): 207. doi: https://doi.org/10.1007/s10549-006-9165-4
Gainford MC, McCready D, Clemons M. Erratum to: The latest is the greatest? Results of a structured lecture about aromatase inhibitor use for breast cancer. Breast Cancer Res Treat. 2006 Apr;96(3):207. doi: 10.1007/s10549-006-9165-4. Epub 2006 Mar 16. PMID: 28303486.
Copy Download .nbib Format: NLM
Erratum to: platinum-based chemotherapy in triple-negative advanced breast cancer.

Breast cancer research and treatment

Villarreal-Garza C, Khalaf D, Bouganim N, Clemons M, Peña-Curiel O, Baez-Revueltas B, Kiss A, Kassam F, Enright K, Verma S, Pritchard K, Myers J, Dent R.
PMID: 25809091
Breast Cancer Res Treat. 2015 Apr;150(3):697. doi: 10.1007/s10549-015-3345-z.

No abstract available.

Cite
Villarreal-Garza C, Khalaf D, Bouganim N, et al. Erratum to: platinum-based chemotherapy in triple-negative advanced breast cancer. Breast Cancer Res Treat. 2015;150(3):697doi: 10.1007/s10549-015-3345-z.
Villarreal-Garza, C., Khalaf, D., Bouganim, N., Clemons, M., Peña-Curiel, O., Baez-Revueltas, B., Kiss, A., Kassam, F., Enright, K., Verma, S., Pritchard, K., Myers, J., & Dent, R. (2015). Erratum to: platinum-based chemotherapy in triple-negative advanced breast cancer. Breast cancer research and treatment, 150(3), 697. https://doi.org/10.1007/s10549-015-3345-z
Villarreal-Garza, Cynthia, et al. "Erratum to: platinum-based chemotherapy in triple-negative advanced breast cancer." Breast cancer research and treatment vol. 150,3 (2015): 697. doi: https://doi.org/10.1007/s10549-015-3345-z
Villarreal-Garza C, Khalaf D, Bouganim N, Clemons M, Peña-Curiel O, Baez-Revueltas B, Kiss A, Kassam F, Enright K, Verma S, Pritchard K, Myers J, Dent R. Erratum to: platinum-based chemotherapy in triple-negative advanced breast cancer. Breast Cancer Res Treat. 2015 Apr;150(3):697. doi: 10.1007/s10549-015-3345-z. PMID: 25809091.
Copy Download .nbib Format: NLM
Erratum to: Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.

Breast cancer research and treatment

Rosenthal E, Moyes K, Arnell C, Evans B, Wenstrup RJ.
PMID: 25850536
Breast Cancer Res Treat. 2015 May;151(1):233. doi: 10.1007/s10549-015-3361-z.

In Table 2 of the original publication, the HGVS and legacy nomenclature were mismatched and the HGVS nomenclature did not correlate with data listed in the table. The corrected table is listed below.

Cite
Rosenthal E, Moyes K, Arnell C, et al. Erratum to: Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry. Breast Cancer Res Treat. 2015;151(1):233doi: 10.1007/s10549-015-3361-z.
Rosenthal, E., Moyes, K., Arnell, C., Evans, B., & Wenstrup, R. J. (2015). Erratum to: Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry. Breast cancer research and treatment, 151(1), 233. https://doi.org/10.1007/s10549-015-3361-z
Rosenthal, Eric, et al. "Erratum to: Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry." Breast cancer research and treatment vol. 151,1 (2015): 233. doi: https://doi.org/10.1007/s10549-015-3361-z
Rosenthal E, Moyes K, Arnell C, Evans B, Wenstrup RJ. Erratum to: Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry. Breast Cancer Res Treat. 2015 May;151(1):233. doi: 10.1007/s10549-015-3361-z. PMID: 25850536.
Copy Download .nbib Format: NLM
Comment on the article Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology by Lubinski et al., Breast Cancer Res Treat 2008 Apr 15.

Hereditary cancer in clinical practice

Irmejs A, Miklasevics E, Strumfa I, Gardovskis J.
PMID: 19804597
Hered Cancer Clin Pract. 2008 Jun 15;6(2):66. doi: 10.1186/1897-4287-6-2-66.

No abstract available.

Cite
Irmejs A, Miklasevics E, Strumfa I, et al. Comment on the article Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology by Lubinski et al., Breast Cancer Res Treat 2008 Apr 15. Hered Cancer Clin Pract. 2008;6(2):66doi: 10.1186/1897-4287-6-2-66.
Irmejs, A., Miklasevics, E., Strumfa, I., & Gardovskis, J. (2008). Comment on the article Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology by Lubinski et al., Breast Cancer Res Treat 2008 Apr 15. Hereditary cancer in clinical practice, 6(2), 66. https://doi.org/10.1186/1897-4287-6-2-66
Irmejs, Arvids, et al. "Comment on the article Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology by Lubinski et al., Breast Cancer Res Treat 2008 Apr 15." Hereditary cancer in clinical practice vol. 6,2 (2008): 66. doi: https://doi.org/10.1186/1897-4287-6-2-66
Irmejs A, Miklasevics E, Strumfa I, Gardovskis J. Comment on the article Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology by Lubinski et al., Breast Cancer Res Treat 2008 Apr 15. Hered Cancer Clin Pract. 2008 Jun 15;6(2):66. doi: 10.1186/1897-4287-6-2-66. PMID: 19804597; PMCID: PMC2735278.
Copy Download .nbib Format: NLM
Correction to: Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung.

Breast cancer research and treatment

McCullar B, Pandey M, Yaghmour G, Hare F, Patel K, Stein MK, Feldman R, Chandler JC, Martin MG.
PMID: 30306431
Breast Cancer Res Treat. 2019 Jan;173(1):243. doi: 10.1007/s10549-018-4974-9.

In the original publication, the sixth author name was published incorrectly as Matthew Stein. The correct author name should read as Matthew K Stein.

Cite
McCullar B, Pandey M, Yaghmour G, et al. Correction to: Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung. Breast Cancer Res Treat. 2019;173(1):243doi: 10.1007/s10549-018-4974-9.
McCullar, B., Pandey, M., Yaghmour, G., Hare, F., Patel, K., Stein, M. K., Feldman, R., Chandler, J. C., & Martin, M. G. (2019). Correction to: Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung. Breast cancer research and treatment, 173(1), 243. https://doi.org/10.1007/s10549-018-4974-9
McCullar, Brennan, et al. "Correction to: Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung." Breast cancer research and treatment vol. 173,1 (2019): 243. doi: https://doi.org/10.1007/s10549-018-4974-9
McCullar B, Pandey M, Yaghmour G, Hare F, Patel K, Stein MK, Feldman R, Chandler JC, Martin MG. Correction to: Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung. Breast Cancer Res Treat. 2019 Jan;173(1):243. doi: 10.1007/s10549-018-4974-9. PMID: 30306431.
Copy Download .nbib Format: NLM
Correction to: Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes.

Breast cancer research and treatment

Volders JH, Negenborn VL, Spronk PE, Krekel NMA, Schoonmade LJ, Meijer S, Rubio IT, van den Tol MP.
PMID: 29327297
Breast Cancer Res Treat. 2018 Feb;168(1):13-15. doi: 10.1007/s10549-017-4632-7.

In the original publication of the article, Table 2 was published incorrectly. The corrected Table 2 is given in this erratum. The original article has been corrected.

Cite
Volders JH, Negenborn VL, Spronk PE, et al. Correction to: Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes. Breast Cancer Res Treat. 2018;168(1):13-15doi: 10.1007/s10549-017-4632-7.
Volders, J. H., Negenborn, V. L., Spronk, P. E., Krekel, N. M. A., Schoonmade, L. J., Meijer, S., Rubio, I. T., & van den Tol, M. P. (2018). Correction to: Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes. Breast cancer research and treatment, 168(1), 13-15. https://doi.org/10.1007/s10549-017-4632-7
Volders, José H, et al. "Correction to: Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes." Breast cancer research and treatment vol. 168,1 (2018): 13-15. doi: https://doi.org/10.1007/s10549-017-4632-7
Volders JH, Negenborn VL, Spronk PE, Krekel NMA, Schoonmade LJ, Meijer S, Rubio IT, van den Tol MP. Correction to: Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes. Breast Cancer Res Treat. 2018 Feb;168(1):13-15. doi: 10.1007/s10549-017-4632-7. PMID: 29327297; PMCID: PMC6828484.
Copy Download .nbib Format: NLM
Erratum to: Contribution of clinical and socioeconomic factors to differences in breast cancer subtype and mortality between Hispanic and non-Hispanic white women.

Breast cancer research and treatment

Martínez ME, Gomez SL, Tao L, Cress R, Rodriguez D, Unkart J, Schwab R, Nodora JN, Cook L, Komenaka I, Li C.
PMID: 28871561
Breast Cancer Res Treat. 2017 Nov;166(1):195. doi: 10.1007/s10549-017-4455-6.

No abstract available.

Cite
Martínez ME, Gomez SL, Tao L, et al. Erratum to: Contribution of clinical and socioeconomic factors to differences in breast cancer subtype and mortality between Hispanic and non-Hispanic white women. Breast Cancer Res Treat. 2017;166(1):195doi: 10.1007/s10549-017-4455-6.
Martínez, M. E., Gomez, S. L., Tao, L., Cress, R., Rodriguez, D., Unkart, J., Schwab, R., Nodora, J. N., Cook, L., Komenaka, I., & Li, C. (2017). Erratum to: Contribution of clinical and socioeconomic factors to differences in breast cancer subtype and mortality between Hispanic and non-Hispanic white women. Breast cancer research and treatment, 166(1), 195. https://doi.org/10.1007/s10549-017-4455-6
Martínez, María Elena, et al. "Erratum to: Contribution of clinical and socioeconomic factors to differences in breast cancer subtype and mortality between Hispanic and non-Hispanic white women." Breast cancer research and treatment vol. 166,1 (2017): 195. doi: https://doi.org/10.1007/s10549-017-4455-6
Martínez ME, Gomez SL, Tao L, Cress R, Rodriguez D, Unkart J, Schwab R, Nodora JN, Cook L, Komenaka I, Li C. Erratum to: Contribution of clinical and socioeconomic factors to differences in breast cancer subtype and mortality between Hispanic and non-Hispanic white women. Breast Cancer Res Treat. 2017 Nov;166(1):195. doi: 10.1007/s10549-017-4455-6. PMID: 28871561.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 287 entries